养正消积胶囊对原发性肝癌肝动脉化疗栓塞术后患者细胞免疫功能及血管形成的影响  

Influence of Yangzheng Xiaoji Capsule Cellular Immune Function and Angiogenesis in Treating Primary Liver Cancer after Arterial Chemoembolization

作　　者：张剑[1] 吴敏[1] 张自森[1] 王利娟[1] 张红巧[1] 师广勇[1] 巴楠[1] 闫琳[1] 郑晓珂[1] 邢鑫[1] 

机构地区：[1]郑州大学第五附属医院肿瘤科,郑州450052

出　　处：《中国实验方剂学杂志》2014年第13期189-192,共4页Chinese Journal of Experimental Traditional Medical Formulae

基　　金：河南省自然科学基金项目(83200450350)

摘　　要：目的:探讨养正消积胶囊对原发性肝癌肝动脉化疗栓塞(TACE)术后患者无进展生存期(PFS)的影响及作用机制。方法:将97例患者随机按住院顺序分为对照组47例和观察组50例。对照组服用复方斑蝥胶囊,3粒/次,2次/d。观察组服用养正消积胶囊,4粒/次,2次/d。疗程:直到疾病出现进展。记录无进展生存期;治疗前及治疗后3个月进行KPS评分及外周血T淋巴细胞亚群和自然杀伤细胞(NK)水平检测;检测治疗前及治疗后3个月血管内皮生长因子(VEGF)、成纤维细胞生长因子(FGF)和血甲胎蛋白(AFP)水平。结果:对照组PFS时间为(17.5±6.2)周,观察组为(21.3±6.9)周,观察组PFS长于对照组(P<0.01);治疗后3个月对照组T淋巴细胞亚群(CD3+,CD4+,CD8+,CD4+/CD8+)和NK与治疗前比较变化不明显;观察组CD3+,CD4+,CD4+/CD8+,NK均比治疗前上升(P<0.01),治疗后3个月观察组CD3+,CD4+,CD4+/CD8+,NK高于对照组(P<0.01),CD8+低于对照组(P<0.01);治疗后3个月两组血清VEGF,bFGF和AFP水平较治疗前下降(P<0.01),观察组血清VEGF,bFGF和AFP水平低于对照组(P<0.01)。结论:养正消积胶囊能延长原发性肝癌TACE术后患者无进展生存期,稳定了患者的生活质量,其作用机制可能与提高患者细胞免疫功能,抑制血管形成有关。Objective： Discuss the influence and mechanism of action of Yangzheng Xiaoji capsule to patients＇ progression free survival （PFS） in treating primary liver cancer after arterial chemoembolization. Method： Ninety-seven patients were randomly divided into control group （47 cases） and observation group （50 cases） by random number table. Patients in the control group received Fufang Banmao capsules, 3 grains/time, 2 times/day. Patients in the observation group received Yangzheng Xiaoji capsule, 4 grains/time, 2 times/day. Treatment was ending when progression of ill appeared. Progression free survival was recorded. Before treatment and at the third mouth after treatment, KPS was graded and level of T lymphocyte subpopulation of peripheral blood and natural killer cell （NK） were detected, vascular endothelial growth factor （VEGF）, fibroblast growth factor （FGF） and alpha fetal protein （AFP） were also detected. Result： PFS in control group were （17.5±6.2） weeks which were （21.3± 6.9） weeks in observation group, which meat PFS in observation group was longer than in control group （P 〈 0.01 ）. Treatment 3 months after the control group T lymphocyte subsets （ CD3^＋ , CD4^＋ , CD8^＋ , CD4^＋/CD8^＋ ） and NK in control group changed indistinctively. But CD3^＋, CD4^＋ , CD4^＋/ CD8^＋ and NK in observation group increased （P 〈 0. 01 ） , and which in observation group were higher than those in control group （P 〈0.01 ）, CD8^＋ in observation group was lower than in control group （P 〈 0.01 ）. After 3 mouths of treatment, compared with the time before treatment, level of serous VEGF, bFGF and AFP decreased （P 〈 0.01 ）, which in observation group were lower than those in control group （P 〈 0.01 ）. Conclusion： Yangzheng Xiaoji capsule can prolong patients＇ progression free survival in treating primary liver cancer after arterial chemoembolization, it stabilized patients＇ quality of lives, and its improving patients＇ cellular

关 键 词：原发性肝癌 养正消积胶囊 无进展生存期 T细胞亚群 自然杀伤细胞 血管内皮生长因子 成纤维细胞生长因子 

分 类 号：R287[医药卫生—中药学]